FDA Chief Addresses Drug Pricing and Advisory Panels with Biotech Leaders.

FDA chief Robert Califf told biotech leaders that drug prices in the US are too high, despite the drug industry's opposition to new mechanisms that could limit how much governments or insurers pay for certain new medicines. Califf has spent much of his career working on new ways of generating decisive evidence for therapies and other medical interventions.